UVE (NYSE: UVE) insider trust discloses planned sale of 25,000 shares
Rhea-AI Filing Summary
A holder of UVE common stock filed an amended notice under Rule 144 to sell 25,000 shares through Wells Fargo Clearing Services on or about 12/30/2025 on the NYSE, with an aggregate market value of $844,398.16. The filing notes that 28,048,881 shares of the same class were outstanding. It also reports that the Stephen Donaghy Trust previously sold 25,000 common shares of UVE on 12/29/2025 for gross proceeds of $851,779.94. The seller represents that they do not know of any material adverse, non‑public information about the issuer’s current or prospective operations.
Positive
- None.
Negative
- None.
FAQ
What does the UVE Form 144/A filing disclose?
The filing discloses that a holder of UVE common stock has filed an amended notice under Rule 144 to sell 25,000 shares through Wells Fargo Clearing Services on or about 12/30/2025 on the NYSE, with an aggregate market value of $844,398.16.
How many UVE shares are planned to be sold and what is their market value?
The notice covers the proposed sale of 25,000 UVE common shares with an aggregate market value of $844,398.16 as provided in the filing.
How many UVE shares are outstanding according to this Form 144/A?
The filing states that there are 28,048,881 UVE common shares outstanding for the class of securities referenced in the proposed sale.
What prior UVE share sales by the same seller are reported?
The filing reports that the Stephen Donaghy Trust sold 25,000 common shares of UVE on 12/29/2025, generating $851,779.94 in gross proceeds during the past three months.
Who is the broker for the planned UVE share sale under Rule 144?
The proposed sale of 25,000 UVE common shares is listed as being handled by Wells Fargo Clearing Services, located at 1 N. Jefferson Ave., St. Louis, MO 63103, with the shares to be sold on the NYSE.
What representation does the seller make about information on UVE?
The person for whose account the securities are to be sold represents by signing that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.